DOTA-chelated radiometal

DOTA-chelated radiometals are complexes formed between the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and radiometal ions, commonly including isotopes such as ^177^Lu, ^90^Y, ^111^In, ^64^Cu, and ^225^Ac[3][4][5][6][7]. DOTA forms highly stable complexes with these radiometals due to its octadentate binding mode utilizing four nitrogen and four carboxylate donors, enveloping the metal ion[3]. The resulting DOTA–radiometal complex can be covalently attached to targeting molecules (e.g., monoclonal antibodies, peptides) for use in targeted radiopharmaceuticals in cancer therapy and diagnostic imaging. While these complexes are not themselves biological therapeutic targets such as receptors or enzymes, they are central intermediates that enable receptor-specific delivery of radiometals to tumors via conjugation with biologically active molecules[4][6][7]. Notable limitations include possible instability with certain large or high-charge metal ions, and preparation constraints (e.g., heating required during chelation, sensitivity to impurities), which can impact the practical use in targeted alpha therapy and other radiotherapeutic contexts[4][5][7]. **Note:** "DOTA-chelated radiometal" is not a therapeutic target but a chemical complex or delivery vehicle; the true biological target in any DOTA-radiometal-based drug is defined by the conjugated targeting vector (such as a somatostatin receptor when using DOTA-peptide radiopharmaceuticals).

Other names

DOTA-radiometal complexDOTA–metal complexDOTA–radiometal conjugate[DOTA]–radiometalDOTA-chelated radioisotope

Targeted delivery of radioisotopes to specific tissues (e.g., via antibody or peptide conjugation), enabling targeted radiotherapy or diagnostic imaging[4][6][7].